Health watchdog reverses decision not to recommend olaparib for patients with genetic fault
The NHS in England is to offer thousands of cancer patients the world’s first cancer drug to target an inherited genetic fault, after a U-turn by the health watchdog.
The National Institute for Health and Care Excellence (Nice) opted last year not to recommend olaparib for breast cancer patients with the so-called “Angelina Jolie gene” because of its high cost. The pioneering drug’s list price is £2,317.50 for one pack of 150mg tablets, excluding VAT.
